Genentech Positions ABT-199 For New Role In AML, Debuts In Hemophilia
Executive Summary
Early data presented at the ASH meeting suggest potential for two oral drugs in the tough-to-treat AML – the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) and a member of the emerging class of MDM2 inhibitors – RG7388.